862377-29-5

Usage

Uses

Used in Pharmaceutical Industry:
S,R,R-DHTBZ is used as a VMAT2 inhibitor for its potential therapeutic effects in various medical conditions.
Used in Asthma Treatment:
S,R,R-DHTBZ is used as a therapeutic agent for asthma, aiming to alleviate symptoms and improve lung function by modulating monoamine levels.
Used in Anxiety Treatment:
S,R,R-DHTBZ is used as an anxiolytic medication, helping to reduce anxiety levels by targeting the VMAT2 and potentially influencing neurotransmitter regulation.
Used in Dementia Treatment:
S,R,R-DHTBZ is used as a potential treatment for dementia, where it may help improve cognitive function and slow down the progression of neurodegenerative diseases by modulating monoamine neurotransmitter storage and release.

Upstream product

• 58-46-8 (3R^*,11bR^*)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzoquinolizin-2-one 
• 924854-62-6 (2R,3S,11bS)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol 
• 1026016-84-1 (3S,11bS)-tetrabenazine 
• 862287-30-7 C₁₉H₂₇NO₂ 
• 1215167-80-8 (11bS)-1,6,7,11b-tetrahydro-9,10-dimethoxy-3-(2-methylpropyl)-4H-benzo[a]quinolizine 
• 862287-32-9 C₂₉H₃₆F₃NO₅ 

Relevant academic research and scientific papers

Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors

Tetrabenazine (TBZ) ((±)-1) and dihydrotetrabenazines (DHTBZ) are potent inhibitors of VMAT2. Herein, a practical chemical resolution of (±)-1 and stereoselective synthesis of all eight DHTBZ stereoisomers are described. The result of VMAT2 binding assay revealed that (+)-1 (Ki = 4.47 nM) was 8000-fold more potent than (-)-1 (Ki = 36,400 nM). Among all eight DHTBZ stereoisomers, (2R,3R,11bR)-DHTBZ ((+)-2: Ki = 3.96 nM) showed the greatest affinity for VMAT2. The (3R,11bR)-configuration appeared to play a key role for VMAT2 binding. In summary, (+)-1, (+)-2, and their derivatives warrant further studies in order to develop more potent and safer drugs for the treatment of chorea associated with Huntington's disease and other hyperkinetic disorders.

3, HB CIS DIHYDROTETRABANEZINE FOR THE TREATMENT OF SCHIZOPHRENIA AND OTHER PSYCHOSES

The invention provides the use of 3,1l b-cis-dihydrotetrabenazine or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prophylaxis or treatment of schizophrenia and other psychoses.

3 , llB-CIS-DIHYDROTETRABENAZINE FOR THE TREATMENT OF A PROLIFERATIVE DISEASE OR AN INFLAMMATION

The invention provides the use of a compound for the manufacture of a medicament for the prophylaxis or treatment of a proliferative disease or an inflammatory disease, the compound being 3,1lb-cis-dihydrotetrabenazine or a pharmaceutically acceptable sal

USE OF 3,1IB-CIS-DIHYDROTETRABENAZINE FOR THE TREATMENT OF SYMPTONS OF HUNTINGTON' S DISEASE

The invention provides 3,1 lb-cis-dihydrotetrabenazine for use in halting or slowing the progress of one or more symptoms of Huntington''s disease in a patient, and more particularly a symptom selected from involuntary movements such as involuntary chorea, tremors and twitches, and degeneration in gait.

DIHYDROTETRABENAZINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The invention provides novel isomers of dihydrotetrabenazine, individual enantiomers and mixtures thereof wherein the dihydrotetrabenazine is a 3,11 b-cis- dihydrotetrabenazine. Also provided are methods for the preparation of the novel isomers, pharmaceutical compositions containing them and their use in treating hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile chorea, tic, tardive dyskinesia and Tourette's syndrome.